HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 million

• HBM Holdings reported 2026 first-half revenue up 20.9% to US$122.49 million, while profit fell 11.16% to US$64.85 million.
• Basic earnings per share slipped 11.11% to US$0.08.
• Research and development costs rose 64.8% to US$29.6 million; administrative expenses more than doubled to US$16.67 million.
• Cash and cash equivalents declined 10.89% to US$359.16 million as of June 30, while total equity climbed 13.81% to US$417.82 million.
• Pipeline updates included batoclimab’s China BLA review in gMG; Windward Bio started Phase II COPD dosing for HBM9378/WIN378.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260910-12328452), on September 10, 2026, and is solely responsible for the information contained therein.